The correctional system presents unique challenges that can interfere with the HIV-infected inmate’s ability to adhere to antiretroviral treatment. One mechanism to facilitate adherence is twice-daily dosing. This article compares safety and efficacy data on five currently available protease inhibitors - amprenavir, indinavir, nelfmavir, saquinavir soft gel capsules, and ritonavir - and examines their adaptability to twice-daily dosing. Movements toward once-daily dosing are discussed, as is the development of new dual protease inhibitor regimens. Simplified dosing strategies along with a comprehensive continuum of care have important benefits for adherence as well as for the inmate’s long-term well-being.
Get full access to this article
View all access options for this article.
References
1.
AlticeF.L., MostashariF., SelwynP.A., CheckoP.J., SinghR., TanguayS., & BlanchetteE.A. (1998). Predictors of HIV infection among newly sentenced male prisoners. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18, 444-453.
2.
ArribasJ.R., LazzarinA., MartinT., MoroniM., VanhoveG., MacleodC., & Collaborative Group on Ritonavir Dose Escalation (CGRDE). (1998 ). Effect of dose escalation on the safety, tolerability and efficacy of ritonavir [Poster 12283]. Presented at the 12th World AIDS Conference, Geneva, Switzerland.
3.
BaillargeonJ., BoruckiM., WilliamsonJ., & DunnK. (1999). Determinants of HIV-related survival among Texas prison inmates. AIDS Patient Care and STDs, 13, 355-361.
4.
BurgerD.M., Hugen, P.W.H., ter Hofstede, H.J.M., KoopmansP.P., StekM., ReissP., & Lange, J.M.A. (1999a). Dose-finding study of a once daily indinavir/ritonavir regimen in healthy volunteers [Abstract 321]. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (p. 13) San Francisco, CA.
5.
BurgerD.M., Hugen, P.W.H., ter Hofstede, H.J.M., KoopmansP.P., Stek, M. Jr., ReissP., & Lange, J.M.A. (1999b). Dose-finding study of a once-daily indinavir/ritonavir regimen in healthy volunteers [Poster 0321]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA.
6.
CarrA., SamarasK., BurtonS., LawM., FreundJ., ChisholmD.J., & CooperD.A. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 12, F51-F58.
7.
CohenC., MogyorosM., SandsM., LentzE., Siemon-HryczykP., PilsonR., DuffF. (1999). TIDBID Study: Fortovase( (FTV) TID regimen compared to FTV BID or FTV + NFV BID regimens in HIV-1-infected patients [Poster]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA.
8.
CohenC., Siemon-HryczykP., PilsonR., HolzknechtB., PhillipsK., KarolC., & PallejaS. (1998). Potent and convenient Fortovase"! SGC BID regimens in combination with two nucleosides or nelfinavir (NFV) plus one nucleoside in HIV infected patients [Poster 12314]. Presented at the 12th World AIDS Conference, Geneva, Switzerland.
9.
Cohen Stuart, J.W.T., SchuurmanR., BurgerD.M., KoopmansP.P., SprengerH.G., JuttmannJ.R., RichterC., MeenhorstP.L., Hoetelmans, R.M.W., KroonF.P., BravenboerB., HamannD., BoucherC.A., & Borleffs, J.C.C. (1999). Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). AIDS, 13, F53-F58.
10.
DavisS.M., CanniffJ.M., AndradasV., CohenC.J., & HellingerJ.A. (1997). Successful ritonavir induction: Intensive patient management [Abstract]. Proceedings of the 4th Conference on Retroviruses and Opportunistic Infections, Chicago, IL.
DrusanoG.L. (1995). Principles of therapy for HIV protease inhibitors [Abstract S110]. Abstracts from the IDSA 33rd Annual Meeting, San Francisco, CA.
13.
FarthingC., NorrisD., SlaterL., PieroneG., Siemon-HyrczykP., PilsonR., PhillipsK., & PallejaS. (1998). Fortovase( (SQV) SGC bid regimens in combination with two nucleosides or nelfinavir (NFV) plus one nucleoside in HIV-1 infected patients [Abstract I-105]. Slide session presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.
14.
GlaserJ.B., & GreifmgerR.B. (1993). Correctional health care: A public health opportunity. Annals of Internal Medicine, 118, 139-145.
15.
Glaxo Wellcome Inc. (1999). Agenerase "! (amprenavir) [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc.
16.
HadiganC., MillerK., CorcoranC., AndersonE., BasgozN., & GrinspoonS. (1999). Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. Journal of Clinical Endocrinology and Metabolism, 84, 1932-1937.
17.
HavlirD.V., & Lange, J.M.A. (1998). New antiretrovirals and new combinations. AIDS, 12 (Suppl. A), S165-S174.
18.
HsuA., GrannemanG.R., & BertzR.J. (1998). Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clinical Pharmacokinetics, 35, 275-291.
19.
JarvisB., & FauldsD. (1998). Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs, 56, 147-167.
20.
JohnsonM., NelsonM., PetersB., ClotetB., PetersenA., & ChangY. (1998). A comparison of BID and TID dosing of nelfinavir when given in combination with stavudine (d4T) and lamivudine (3TC) for up to 48 weeks [Abstract I-216]. Poster presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.
21.
Jurgens, R.E.F. (1998). Promoting the rights of prisoners: Condoms, bleach, needles, methadone and care in prisons [Abstract 44191]. Proceedings of the 12th World AIDS Conference (p. 537), Geneva, Switzerland.
22.
KakudaT.N., StrubleK.A., & PiscitelliS.C. (1998). Protease inhibitors for the treatment of human immunodeficiency virus infection. American Journal of Health-System Pharmacy, 55, 233-254.
23.
KempfD., RodeR., XuY., SunE., JapourA., DannerS., BoucherC., LeonardJ., & MollaA. (1997). The durability of response to protease inhibitor therapy is predicted by viral load [Abstract 62]. Proceedings of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication (p. 41), St. Petersburg, FL.
24.
KirkO., KatzensteinT.L., GerstoftJ., MathiesenL., NielsenH., PedersenC., & LundgrenJ.D. (1999). Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomized trial. AIDS, 13, F9-F16.
25.
LoJ.C., MulliganK., TaiV.W., AlgrenH., & SchambelanM. (1998). "Buffalo hump" in men with HIV-1 infection. Lancet, 351, 867-870.
26.
MacherA.M., & GoosbyE.P. (1998). Primary HIV infection/acute retroviral syndrome: An intervention opportunity for correctional facilities. Journal of Correctional Health Care, 5, 51-62.
27.
MahonN. (1996). New York inmates’ HIV risk behaviors: The implications for prevention policy and programs. American Journal of Public Health, 86, 1211-1215.
28.
MellorsJ., JapourA.J., CameronD.W., FarthingC., CohenC., MarkowitzM., PoretzD., FollansbeeS., HoD., McMahonD., BergJ., NievesJ., XuY., RodeR., SalgoM., LeonardJ., & SunE. (1998). Ritonavir (RTV)- saquinavir (SQV) in protease inhibitor-naïve patients after 72 weeks [Poster 12295]. Presented at the 12th World AIDS Conference, Geneva, Switzerland.
29.
MillerK.D., JonesE., YanovskiJ.A., ShankarR., FeuersteinI., & FalloonJ. (1998). Visceral abdominal-fat accumulation associated with use of indinavir. Lancet, 351, 871-875.
30.
MoyleG.J., & BaldwinC. (1999). Lipid abnormalities during saquinavir soft-gel(based highly active antiretroviral therapy [Letter]. Journal of Acquired Immune Deficiency Syndromes, 21, 423-424.
31.
MurphyR.E. (1999). New antiretroviral drugs, part I: PIs. AIDS Clinical Care, 11, 35-37.
32.
MurphyR.L., GulickR.M., DeGruttolaV., D’AquilaR.T., EronJ.J., SommadossiJ.P., CurrierJ.S., SmeatonL., FrankI., CaliendoA.M., GerberJ.G., TungR., & KuritzkesD.R. for the AIDS Clinical Trials Group 347 Study Team. (1999). Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. The Journal of Infectious Diseases, 179, 808-816.
33.
NelsonM.R., Morris-JonesS., ShaveA., MoyleG., RichardsonC., & GazzardB.G. (1998). The use of twice daily indinavir in highly active antiretroviral therapy [Abstract I-209]. Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.
34.
O’BrienW.A., AtkinsonT.A., HanX., SovaM., & EastJ. (1999a). Combination therapy with indinavir and ritonavir in antiretroviral-experienced patients [Abstract 2209]. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (p. 539), San Francisco, CA.
35.
O’BrienW.A., AtkinsonT.L., HanX., SovaM., & EastJ. (1999b). Combination therapy with indinavir and ritonavir in antiretroviral treatment-experienced patients [Poster 2209]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA.
36.
PerryC.M., & NobleS. (1998). Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs, 55, 461-486.
37.
PR Newswire. (9/18/1998). Merck discontinues study arms with twice-daily dosing of Crixivan(R) in combination with reverse transcriptase inhibitors. Twice-daily studies with Crixivan and other protease inhibitors continue. Available at: http://nrstg2s.djnr.com/cqi-bin/DJIntera...Highlight=on&D oe; http://nrstg2s.djnr.com/cgi-bin/DJIntera...Highlight = on&DocType = TextOnly&View = View 1. Accessed July 20, 1999.
38.
SaagM.S., KilbyM., EhrensingE., GizziN.A., Siemon-HryczykP., BussN., & OoC.Y. (1999). Saquinavir systemic exposure and safety of once daily administration of Fortovase"! (saquinavir) soft gel capsule (FTV) in combination with low-dose ritonavir (RTV) [Abstract 330]. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (p. 17), San Francisco, CA.
39.
SaagM.S., OoC., GizziN.A., Siemon-HryczykP., de CaprariisP.J., & BussN. (1999). Favorable saquinavir systemic exposure and safety of once daily administration of Fortovase( (saquinavir) soft gel capsule (FTV) in combination with low dose ritonavir (RTV) [Poster 50]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA.
40.
SaahA., WinchellG., SeniukM., NesslyM., & DeutschP. (1999a). Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) and ritonavir (RTV) combinations in a once-daily regimen in healthy volunteers (Merck 089) [Abstract 329]. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (p. 17), San Francisco, CA.
41.
SaahA., WinchellG., SeniukM., NesslyM., & DeutschP. (1999b). Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) and ritonavir (RTV) combinations in a once-daily regimen in healthy volunteers (Merck 089) [Poster 329]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA.
42.
SaahA., WinchellG., SeniukM., MehrotraD., & DeutschP. (1999). Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV)-ritonavir (RTV) combinations in healthy volunteers (Merck 078) [Poster 362] . Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL.
43.
Saint-MarcT., Poizot-MartinI., PartisaniM., FabreJ., & TouraineJ.L. (1999). A syndrome of lipodystrophy in patients receiving a stable nucleoside-analogue therapy [Abstract 653]. Proceedings of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL.
44.
SchapiroJ.M., WintersM., LawrenceJ., NorrisJ., & MeriganT.C. (1997). Clinical and genotypic cross-resistance between the protease inhibitors saquinavir and indinavir [Abstract 87]. Proceedings of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication (pp. 57-58), St. Petersburg, FL.
SkolnickP.R., Siemon-HryczykP., DrakeJ., DuffF., BussN. (1999). Serum lipid levels in HIV-positive adults during saquinavir-containing combination therapy [Poster 35]. Presented at the 1 st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, CA.
47.
SlaterL., SensionM., FeinbergJ., PobleteR., Siemon-HryczykP., PilsonR., & PallejaS. (1999). Fortovase BID regimens in HIV-1 infected patients: Combination with 2 nucleoside analogs (NAs) or with nelfinavir plus 1 NA [Poster 390]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL.
48.
TebasP., KaneE., KlebertM., SimpsonJ., PowderlyW.G., & HenryK. (1998). Virologic responses to a ritonavir/saquinavir containing regimen in patients who have previously failed nelfinavir [Abstract]. Proceedings of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL.
49.
TsoukasC., & ReddyD.A. (1999). Predictive value of response at 12 and 24 weeks for durability of response in a study of the soft gelatin capsule formulation of saquinavir (SQV-SGC) plus 2 nucleosides in treatment-naive HIV-1-positive patients. Proceedings of the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL.
U.S. Department of Justice, Office of Justice Programs. (April 1999). Correctional populations in the United States, 1996. Available at: http://www.ojp.usdoj.gov/bjs/prisons.htm. Accessed July, 30, 1999.
52.
U.S. Department of Justice, Office of Justice Programs, & GilliardD.K. (March 1999). Prison and jail inmates at midyear 1998. Available at: http://www.ojp.usdoj.gov/bjs/prisons.htm. Accessed July 30, 1999.
53.
U.S. Department of Justice, Office of Justice Programs, HammettT.M., HarmonP., & MaruschakL.M. (July 1999). Issues and practices: 1996-1997 update: HIV/AIDS, STDs, and TB in correctional facilities. Available at: http://www.ojp.usdoj.gov/bjs/prisons.htm. Accessed August 15, 1999.
54.
VanhoveG.F., SchapiroJ.M., WintersM.A., MeriganT.C., & BlaschkeT.F. (1996). Patient compliance and drug failure in protease inhibitor monotherapy [Letter]. Journal of the American Medical Association, 276, 1955-1956.
WorkmanC., MussonR., DyerW., & SullivanJ. (1998). Novel double protease combinations-combining indinavir (IDV) with ritonavir (RTV): Results from first study [Abstract 22372]. Proceedings of the 12th World AIDS Conference (p. 338), Geneva, Switzerland.
